Clinical and MRI features according to clinical tenderness at MCP joints (MCPJs 2–5) for CCP+ and RA subjects (n=162)
| Nontender MCPJs n=507 | Tender MCPJs n=141 | |
| Age: mean (SD) | 50.6 (13.7) | 52.2 (13.9) |
| Female | 71% (358) | 84% (118) |
| Group CCP +at risk | 66% (337) | 18% (25) |
| ERA | 26% (132) | 37% (52) |
| LRA | 7% (38) | 38% (54) |
| Synovitis >0 | 20% (101) | 37% (52) |
| Synovitis >1 | 6% (30) | 19% (27) |
| BME >0 | 4% (21) | 14% (20) |
| Tenosynovitis >0 | 30% (153) | 49% (69) |
| Erosions>0 | 3% (17) | 13% (18) |
| ITI | 12% (59) | 28% (40) |
BME, bone marrow oedema;ERA, early RA patients;ITI, interosseous tendon inflammation; LRA, late RA patients;MCPJS, metacarpophalangeal joints;RA, rheumatoid arthritis; CCP +at risk, anti-CCP-positive at-risk individuals.